Learn More: Pregnancy and Lactation Studies
Completed Studies
About the CRIB Study
CRIB was a pharmacokinetic study assessing the potential level of placental transfer of certolizumab pegol (CZP) from pregnant women to their infants. The study followed sixteen women (= 30 weeks gestation) who were already receiving CZP at approved doses.
Click here to access the full study publication
About the CRADLE Study
The primary objectives of the CRADLE pharmacokinetic study were to determine the concentration of certolizumab pegol (CZP) in human breast milk and the average daily infant dose, an estimation of the daily dose of maternal CZP ingested by the breastfeeding infant.
Click here to access the full study publication
Ongoing Studies
About the CHERISH Study
The purpose of the study is to assess systemic certolizumab pegol (CZP) exposure, the formation of anti-CZP antibodies and safety of CZP across the course of pregnancy in study participants with chronic inflammatory diseases.
Click here to access a more detailed description of the study and eligibility criteria